Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04883957 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies

StatusCompleted
PhasePhase 1
SponsorBeiGene
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fields
  2. Trial completed Primary and study completion dates changed from estimate of Aug 31, 2026 to Sep 1, 2026 · Eligibility criteria expanded, about 10 words · Secondary endpoints: details revised at 3 of 12 entries Show 3 more changesShow less
    • Primary and study completion dates changed from estimate of Aug 31, 2026 to Sep 1, 2026
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 3 of 12 entries
  3. Primary and study completion pushed from Jun 2026 to Aug 31, 2026v14
  4. Primary and study completion dates: Apr 2026 to Jun 2026v13
  5. Re-verified, no change to tracked fieldsv12
Show 10 earlier versionsHide 10 earlier versions
  1. Study sites: 10 to 11v11
  2. Re-verified, no change to tracked fieldsv10
  3. Primary and study completion dates: May 2024 to Apr 2026v9
  4. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 70 to confirmed 64 · Site details revised at 10 of 10 sitesv8 Show 2 more changesShow less
    • Enrollment target: estimated 70 to confirmed 64
    • Site details revised at 10 of 10 sites
  5. Study sites: 11 to 10v7
  6. Re-verified, no change to tracked fieldsv6
  7. Study sites: 1 to 11v5
  8. Re-verified, no change to tracked fieldsv4
  9. Enrollment target: 40 to 70v3
  10. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jun 2021 to Jul 5, 2021 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Jun 2021 to Jul 5, 2021
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
BeiGene
37 trials monitored
See 1 trial at risk
The purpose of this study is to evaluate the safety and tolerability of BGB-11417 monotherapy, define the maximum tolerated dose (MTD) or maximum administered dose and the recommended Phase 2 dose (RP2D) of BGB-11417 monotherapy for the selected B-cell malignancy dose finding cohorts, and evaluate the safety and tolerability of the ramp-up dosing schedule in the evaluated disease types.
Trial Details
NCT Number NCT04883957
Lead Sponsor BeiGene
Conditions Mature B-cell Malignancies
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov